Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) is now available.
Clarity Pharmaceuticals has released its 2026 interim report and half-year financial statements for the period ended 31 December 2025, outlining key operational and corporate highlights. The report details progress in clinical and regulatory development, product updates on SAR-bisPSMA and SARTATE, and advances in discovery programs, manufacturing, and supply chain.
The interim report also includes the directors’ report, audited financial statements, and corporate directory, providing a comprehensive snapshot of the company’s financial position and governance. This disclosure offers stakeholders insight into Clarity’s operational momentum, resource allocation, and readiness to scale its radiopharmaceutical pipeline in a competitive oncology market.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$6.40 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd. is an Australian biotechnology company focused on developing radiopharmaceuticals for oncology. Its portfolio includes SAR-bisPSMA and SARTATE, as well as discovery programs aimed at advancing targeted cancer diagnostics and therapies, supported by in-house manufacturing and a global network of collaborators.
Average Trading Volume: 2,178,156
Technical Sentiment Signal: Buy
Current Market Cap: A$1.34B
Find detailed analytics on CU6 stock on TipRanks’ Stock Analysis page.